MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Open

SectorGezondheidszorg

31 -0.9

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

30.32

Max

Belangrijke statistieken
By Trading Economics
Inkomsten	-14M -81M
Verkoop	75K 75K
EPS	-1.22
Winstmarge	-108,422.667
Werknemers	198
EBITDA	-7.8M -81M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+72.46% upside

Dividenden
By Dow Jones
Volgende Winsten	6 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	346M 2B
Vorige openingsprijs	31.9
Vorige sluitingsprijs	31

Nieuwssentiment

By Acuity

100%

335 / 349 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 apr 2026, 17:11 UTC

Belangrijke Marktbewegers

Belangrijke Nieuwsgebeurtenissen

Home Depot Shares Hit 52-Week Low as Iran War Threatens Housing Rebound

2 apr 2026, 17:10 UTC

Belangrijke Nieuwsgebeurtenissen

ECB's Next Move Likely a Rate Rise, But Timing Unclear Amid Iran War, Villeroy Says

3 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

How Insulated Is the U.S. Economy From the Iran War? -- WSJ

2 apr 2026, 23:47 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Nikkei Might Rise After Thursday's Selloffs -- Market Talk

2 apr 2026, 21:05 UTC

Acquisities, Fusies, Overnames

Starbucks: Under the Terms of the Agreement, Funds Managed by Boyu Cap Now Hold a 60% Stake in Starbucks China Retail Ops >SBUX

2 apr 2026, 21:05 UTC

Acquisities, Fusies, Overnames

Starbucks: Retains 40% Ownership Interest and Continues to Own and License the Brand and Intellectual Property to JV >SBUX

2 apr 2026, 21:05 UTC

Acquisities, Fusies, Overnames

Starbucks: Joint Venture Is Designed to Enhance Starbucks Ability to Expand Footprint, Deepen Local Relevance >SBUX

2 apr 2026, 21:05 UTC

Acquisities, Fusies, Overnames

Starbucks and Boyu Cap: Finalize Joint Venture to Accelerate Long-Term Growth in China

2 apr 2026, 21:01 UTC

Belangrijke Nieuwsgebeurtenissen

Investors Waver after Trump Speech on Iran, Ending Two-Day Surge in Stocks -- WSJ

2 apr 2026, 20:59 UTC

Acquisities, Fusies, Overnames

Starbucks and Boyu Capital Finalize China JV

2 apr 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

2 apr 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

2 apr 2026, 20:41 UTC

Winsten

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2 apr 2026, 20:32 UTC

Marktinformatie

Higher Gas Prices Intensify K-Shaped Economy -- Market Talk

2 apr 2026, 20:30 UTC

Acquisities, Fusies, Overnames

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 apr 2026, 20:09 UTC

Marktinformatie

Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

2 apr 2026, 20:01 UTC

Acquisities, Fusies, Overnames

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 apr 2026, 19:46 UTC

Marktinformatie

Is Oil the New GameStop? -- Market Talk

2 apr 2026, 19:35 UTC

Marktinformatie

U.S. Natural Gas Falls As Storage Injection Season Gets Under Way -- Market Talk

2 apr 2026, 19:29 UTC

Acquisities, Fusies, Overnames

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 apr 2026, 19:24 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Jump Ahead of Long Weekend -- Market Talk

2 apr 2026, 19:20 UTC

Marktinformatie

Nike Has Yet to Show That a Turnaround is on Horizon -- Market Talk

2 apr 2026, 19:01 UTC

Acquisities, Fusies, Overnames

Union Pacific: ATDA Agreement to Guarantee Jobs for Life for Union Employees After Norfolk Southern Deal

2 apr 2026, 19:00 UTC

Acquisities, Fusies, Overnames

Union Pacific: Agreement Reached With American Train Dispatchers Association

2 apr 2026, 18:24 UTC

Acquisities, Fusies, Overnames

Globalstar Stock Rises on Amazon Deal Report. Why Apple Could Scuttle the Launch. -- Barrons.com

2 apr 2026, 17:44 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Supply Squeeze Puts Refiners in a Quandary -- Market Talk

2 apr 2026, 17:32 UTC

Belangrijke Nieuwsgebeurtenissen

Amazon to Boost Fuel Surcharges on Third-Party Sellers as Costs Rise -- Barrons.com

2 apr 2026, 17:26 UTC

Winsten

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2 apr 2026, 17:17 UTC

Marktinformatie

Shares of Canadian Exports Heading to U.S. Continues to Slide -- Market Talk

2 apr 2026, 17:09 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Holds Gains After Trump Speech Disappointed Market -- Market Talk

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

72.46% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 53.91 USD 72.46%

Hoogste 90 USD

Laagste 24 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.